APA (7th ed.) Citation

Shiming He, Chunyan Zhao, Hongyu Tao, Weijin Sheng, Ruijuan Gao, Xiujun Liu, & Yongsu Zhen. (2022). A recombinant scFv antibody-based fusion protein that targets EGFR associated with IMPDH2 downregulation and its drug conjugate show therapeutic efficacy against esophageal cancer. Taylor & Francis Group.

Chicago Style (17th ed.) Citation

Shiming He, Chunyan Zhao, Hongyu Tao, Weijin Sheng, Ruijuan Gao, Xiujun Liu, and Yongsu Zhen. A Recombinant ScFv Antibody-based Fusion Protein That Targets EGFR Associated with IMPDH2 Downregulation and Its Drug Conjugate Show Therapeutic Efficacy Against Esophageal Cancer. Taylor & Francis Group, 2022.

MLA (9th ed.) Citation

Shiming He, et al. A Recombinant ScFv Antibody-based Fusion Protein That Targets EGFR Associated with IMPDH2 Downregulation and Its Drug Conjugate Show Therapeutic Efficacy Against Esophageal Cancer. Taylor & Francis Group, 2022.